Struggling biotech Epix Pharmaceuticals goes bust

Courtesy Newsvine - business  Mon, 07/20/2009 - 17:39

Epix, a struggling biotechnology firm working with British drug maker GlaxoSmithKline PLC to develop an Alzheimer's disease drug, says it is winding down its operations and selling off assets to pay off creditors.


 

Related items

GSK receives EU approval for prostate drug
Pharmaceutical company GlaxoSmithKline PLC said Wednesday it has received European approval for Duodart, a two-in-one drug for the treatment of the symptoms of an enlarged prostate.

FDA rejects GlaxoSmithKline nausea, vomiting drug
The U.S. Food and Drug Administration has rejected GlaxoSmithKline PLC's application to approve an experimental drug for nausea and vomiting.

Glaxo signs deal with Concert on early stage drugs
GlaxoSmithKline PLC signed a potential $1 billion deal with U.S. biotech company Concert Pharmaceuticals on Tuesday to access deuterium-containing medicines, a deal that will beef up its...

BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
The X5 Stereo Bluetooth Headset is a portable multi-function device utilizing the latest cutting edge technologies allowing you to stream high quality music and make voice calls using a...

Uniden TRU9496 2-Line Corded/Cordless Digital...
With the Uniden TRU9496 5.8 GHz Digital 2-Line Expandable Phone System is the next generation of 5.8 GHz cordless phones. It's a full-featured digital answerer, with a Dialing keypad and a...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
We apologize for the inconvenience. Please help fight spam.
business.marc8.com